CURRENT RESEARCH INTERESTS
Cancer and stem cell biology, single cell analysis technology, hematopoiesis, immunology.
With a career path traversing clinical medicine, molecular genetics and systems biology, Dr. Tian is primarily interested in applying the powerful systems approach with the enabling genomics, single cell transcriptomics and proteomics technologies to address some of the most pressing issues pertaining to human health: cancer and stem cell biology, immunity, and disease biomarker discovery. He directs the interdisciplinary cancer and stem cell group at ISB striving to dissect the clonal origin of cancer heterogeneity, aiming to identify the tumor-initiating cells and the underlying genomic landscape and physical properties for defining their tumorigenic activities. Dr. Tian has led the development of gene signature panels for cancer patient stratification, and has elucidated protein interaction networks and relevant phosphorylation events in the Wnt signaling pathway for potential therapeutic targeting. He also contributed to the molecular characterization of multiple Th cell subsets (e.g. Th17, follicular T cells) through transcriptomic profiling and genome-wide mapping of protein-DNA interactions.
Dr. Tian collegially reaches out to local and national medical research communities (UW-Medicine, Swedish Hospital, FHCRC, MD Anderson) to disseminate ISB strategy and technologies. His research has been supported by multiple NIH and DoD program/center projects, including a highly competitive R01 award addressing NCIís provocative questions. Dr. Tian is on faculty of the UW-Institute for Stem Cell & Regenerative Medicine (ISCRM). He has also been a visiting professor at Chinese Academy of Medical Sciences and Chinese Academy of Sciences, and served on grant review panels around the world (US, UK, France, Switzerland, EU, and China).
Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, Nurieva RI, Yan X, Chen P, van der Flier LG, Nakatsukasa H, Neelapu SS, Chen W, Clevers H, Tian Q, Qi H, Wei L, Dong C. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature. 2014 Jan 19. doi: 10.1038/nature12910.
Liu X, Yan X, Zhong B, Nurieva RI, Wang A, Wang X, Martin-Orozco N, Wang Y, Chang SH, Esplugues E, Flavell RA, Tian Q, Dong C. Bcl6 expression specifies the T follicular helper cell program in vivo. J Exp Med. 2012 Sep 24;209(10):1841-52, S1-24. Epub 2012 Sep 17.
Hood L* and Tian Q*. Systems approaches to biology and disease enable translational systems medicine. Genomics Proteomics Bioinformatics. 2012 Aug;10(4):181-5. doi: 10.1016/j.gpb.2012.08.004. Epub 2012 Aug 23.
Tian Q*, Price ND, Hood L*. Systems Cancer Medicine: Towards Realization of Predictive, Preventive, Personalized, and Participatory (P4) Medicine. J Intern Med. 2012 Feb;271(2):111-21. doi: 10.1111/j.1365-2796.2011.02498.x.
Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, Price ND, Hood LE, Tian Q*. A CD133-related Gene Expression Signature Identifies an Aggressive Glioblastoma Subtype with Excessive Mutations. Proc Natl Acad Sci U S A. 2011 Jan 25; 108(4):1591-6. Epub 2011 Jan 10.
Reynolds JM, Pappu BP, Peng J, Martinez GJ, Zhang Y, Chung Y, Ma L, Yang XO, Nurieva RI, Tian Q, Dong C. Toll-like Receptor 2 Signaling in CD4(+) T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune Disease. Immunity. 2010 May 28;32(5):692-702. Epub 2010 Apr 29.
Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009 Apr;30(4):576-87. Epub 2009 Apr 9.
Majeti R§, Becker MW§, Tian Q§, Lee TL, Yan X, Liu R, Chiang JH, Hood L, Clarke MF, Weissman IL. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3396-401. (§equal contribution).
Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, Dong C. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity. 2008 Jul;29(1):138-49. Epub 2008 Jul 3. PMCID: PMC2556461.
Price ND, Foltz G, Madan A, Hood L, and Tian Q*. Systems biology and cancer stem cells. J Cell Mol Med. 2008 Jan-Feb;12(1):97-110.
Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007 Jul 26;448(7152):480-3. Epub 2007 Jun 20.
He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, Dirisina R, Porter-Westpfahl KS, Hembree M, Johnson T, Wiedemann LM, Barrett TA, Hood L, Wu H, Li L. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nature Genetics, 2007,Feb;39(2):189-98.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology, 2005 Nov;6(11):1133-41. Epub 2005 Oct 2.
Tian Q*, Feetham MC, Tao WA, He XC, Li L, Aebersold R, Hood L. Proteomic analysis identifies that 14-3-3zeta interacts with beta-catenin and facilitates its activation by Akt. Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15370-5.
Tian Q*, Stepaniants SB*, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics. 2004 Oct;3(10):960-9. Epub 2004 Jul.